FY2022 Earnings Estimate for Provention Bio, Inc. Issued By Chardan Capital (NASDAQ:PRVB)

Provention Bio, Inc. (NASDAQ:PRVBGet Rating) – Analysts at Chardan Capital boosted their FY2022 earnings per share estimates for shares of Provention Bio in a research note issued on Monday, November 21st. Chardan Capital analyst Y. Livshits now anticipates that the company will post earnings of ($1.30) per share for the year, up from their prior estimate of ($1.32). Chardan Capital currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Provention Bio’s current full-year earnings is ($1.67) per share. Chardan Capital also issued estimates for Provention Bio’s FY2023 earnings at ($1.28) EPS.

A number of other equities analysts have also recently issued reports on the company. Oppenheimer upped their target price on Provention Bio from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Friday, November 18th. SVB Leerink upped their target price on Provention Bio from $16.00 to $19.00 and gave the stock an “outperform” rating in a report on Monday. Finally, Jefferies Financial Group upped their target price on Provention Bio from $18.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, November 18th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Provention Bio presently has a consensus rating of “Buy” and a consensus target price of $21.40.

Provention Bio Price Performance

Provention Bio stock opened at $9.41 on Thursday. Provention Bio has a 52 week low of $3.18 and a 52 week high of $9.65. The stock has a fifty day moving average of $6.65 and a 200-day moving average of $5.13. The company has a debt-to-equity ratio of 0.16, a quick ratio of 7.58 and a current ratio of 7.58. The stock has a market capitalization of $820.46 million, a P/E ratio of -6.03 and a beta of 2.36.

Institutional Investors Weigh In On Provention Bio

Institutional investors have recently made changes to their positions in the stock. Bioimpact Capital LLC bought a new stake in shares of Provention Bio in the 2nd quarter valued at about $2,370,000. Rice Hall James & Associates LLC grew its position in shares of Provention Bio by 2.6% in the 2nd quarter. Rice Hall James & Associates LLC now owns 225,785 shares of the company’s stock valued at $903,000 after buying an additional 5,720 shares during the last quarter. Amalgamated Bank bought a new stake in shares of Provention Bio in the 1st quarter valued at about $49,000. Sigma Planning Corp grew its position in shares of Provention Bio by 22.3% in the 2nd quarter. Sigma Planning Corp now owns 153,690 shares of the company’s stock valued at $615,000 after buying an additional 28,070 shares during the last quarter. Finally, OLD Mission Capital LLC bought a new stake in shares of Provention Bio in the 2nd quarter valued at about $41,000. Institutional investors own 37.39% of the company’s stock.

About Provention Bio

(Get Rating)

Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease.

Further Reading

Earnings History and Estimates for Provention Bio (NASDAQ:PRVB)

Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.